Lisata Therapeutics, Inc.
Lisata Therapeutics, Inc. (LSTA) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
lsta · pe ratio · data through Dec 31, 2025
Core PE Ratio Metrics
Trailing 12 months · TTMThe price-to-earnings (P/E) ratio for Lisata Therapeutics, Inc. (LSTA) measures how much investors pay for each dollar of the company's trailing earnings. LSTA's current PE ratio of N/A is calculated by dividing its stock price of $3.48 by its TTM earnings per share of -$1.82.
Source: FMP · /ratios-ttm · /analyst-estimates · 2025-12-31
PE Ratio History
2006 – 2025 · Annual▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)
PE Ratio vs Peers
Biotechnology · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
Lisata Therapeutics, Inc.You LSTA | $32M | N/A | — | -$1.82 |
 CASI Pharmaceuticals, Inc. CASI | $2M | N/A | — | -$2.56 |
 CollPlant Biotechnologies Ltd. CLGN | $5M | N/A | — | -$0.94 |
 Clearside Biomedical, Inc. CLSD | $2M | N/A | — | -$6.98 |
 Enlivex Therapeutics Ltd. ENLV | $17M | 0.03x | — | $27.04 |
 Klotho Neurosciences, Inc. KLTO | $20M | N/A | — | -$0.32 |
 MetaVia Inc. MTVA | $5M | N/A | — | -$7.35 |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
Annual PE Ratio History
| Fiscal Year End | PE Ratio | EPS (TTM) | YoY Change | PE vs Max |
|---|---|---|---|---|
2025-12-31Latest FY2025 | — | $-1.91 | — | |
2024-12-31 FY2024 | — | $-2.40 | — | |
2023-12-31 FY2023 | — | $-2.58 | — | |
2022-12-31 FY2022 | — | $-10.47 | — | |
2021-12-31 FY2021 | — | $-7.45 | — | |
2020-12-31 FY2020 | — | $-7.92 | — | |
2019-12-31 FY2019 | — | $-29.20 | — | |
2018-12-31 FY2018 | — | $-25.03 | — | |
2017-12-31 FY2017 | 1.53x | $36.25 | — | |
2016-12-31 FY2016 | — | $-74.80 | — |
▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for Lisata Therapeutics, Inc. (LSTA) measures how much investors pay for each dollar of the company's trailing earnings. LSTA's current PE ratio of N/A is calculated by dividing its stock price of $3.48 by its TTM earnings per share of -$1.82.
Frequently asked questions
LSTA pe ratio · 6 questionsLSTA's current PE ratio is N/A as of 2026-06-09, based on a stock price of $3.48 and TTM EPS of -$1.82. Data sourced from Financial Modeling Prep via LSTA's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Lisata Therapeutics, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-09